Krypton Kr 81M

CHEMBL1201096 Phase 4 Approuvé Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
80.9 g/mol
LogP
Phase
4

A short-lived radioactive isotope of krypton used in ventilation-perfusion lung scanning to assess airflow distribution and diagnose conditions such as pulmonary embolism. It is inhaled and quickly exhaled, providing real-time imaging.

Masse moléculaire

80,9166 g/mol

TPSA

0,00 Ų

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Structure 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

[81Kr]

InChI

InChI=1S/Kr/i1-3

Molecular Formula

Kr

HBD / HBA

- / -

Liaisons Rotatives

0

Atomes Lourds

1

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Foire aux questions

A short-lived radioactive isotope of krypton used in ventilation-perfusion lung scanning to assess airflow distribution and diagnose conditions such as pulmonary embolism. It is inhaled and quickly exhaled, providing real-time imaging.

Yes, Krypton Kr 81M is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201096. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 66380. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Avertissement médical

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.